Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 2/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22037294 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNATDP1GBA1 | |
| SCHEMBL3787675 | 0.76 | — | — | |
| SCHEMBL19736584 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNATDP1GBA1 | |
| SCHEMBL12957660 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNATDP1GBA1 | |
| SCHEMBL16016300 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL890314 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL18736267 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL4911680 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL6450045 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL4911675 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152196-A1 | SAPONIN-BASED VACCINE ADJUVANTS | THE UAB RESEARCH FOUNDATION | 2022-05-19 | — | — | US | disclosed |
| EP-2561085-B1 | CELL-BASED PRODUCTION OF NONULOSONATES | NAT RES COUNCIL CANADA (CA) | 2019-08-14 | — | — | EP | disclosed |
| US-20190127411-A1 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | CRODA INTERNATIONAL PLC (GB) | 2019-05-02 | — | — | US | disclosed |
| US-9512455-B2 | Cell-based production of nonulosonates | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2016-12-06 | — | — | US | disclosed |
| US-20160022826-A1 | CARBOHYDRATE-MODIFIED GLYCOPROTEINS AND USES THEREOF | LUMOS PHARMA, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140356912-A1 | CELL-BASED PRODUCTION OF NONULOSONATES | UNIVERSITY OF OTTAWA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-8841099-B2 | Cell-based production of nonulosonates | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2014-09-23 | — | — | US | disclosed |
| WO-2014077960-A1 | SYNTHESIS OF CARBOHYDRATE-BASED SURFACTANTS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130196381-A1 | CELL-BASED PRODUCTION OF NANULOSONATES | UNIVERSITY OF OTTAWA (CA) | 2013-08-01 | — | — | US | disclosed |
| WO-2012082635-A1 | SYNTHETIC OLIGOSACCHARIDE GROUP A STREPTOCOCCUS | ANCORA PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127411-A1 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | LYPLAL1, LNPEP, PHOSPHO1 | ALDH1A1 4821/4885TSHR 4094/4885LMNA 1526/4885 |
| US-20220152196-A1 | SAPONIN-BASED VACCINE ADJUVANTS | ST3GAL3, B3GAT3, CSGALNACT1 | ALDH1A1 4710/4885TSHR 3151/4885LMNA 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.